<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Anesthesiol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Anesthesiol</journal-id><journal-title-group><journal-title>BMC Anesthesiology</journal-title></journal-title-group><issn pub-type="epub">1471-2253</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27852230</article-id><article-id pub-id-type="pmc">5112723</article-id><article-id pub-id-type="publisher-id">277</article-id><article-id pub-id-type="doi">10.1186/s12871-016-0277-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The effect of preoperative dexamethasone on pain 1&#x000a0;year after lumbar disc surgery: a follow-up study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nielsen</surname><given-names>Rikke Vibeke</given-names></name><address><phone>0045 60926839</phone><email>rikkevibeke@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fomsgaard</surname><given-names>Jonna</given-names></name><address><email>jonna.storm.fomsgaard@regionh.dk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mathiesen</surname><given-names>Ole</given-names></name><address><email>omat@regionsjaelland.dk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dahl</surname><given-names>J&#x000f8;rgen Berg</given-names></name><address><email>jbdahl@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Department of Neuroanaesthesiology, Rigshospitalet, Glostrup University Hospital, Nordre Ringvej 57, 2600 Glostrup, Denmark </aff><aff id="Aff2"><label>2</label>Department of Neuroanaesthesiology, Rigshospitalet, Glostrup University Hospital, Glostrup, Denmark </aff><aff id="Aff3"><label>3</label>Department of Anaesthesiology, University Hospital Zealand, K&#x000f8;ge Hospital, K&#x000f8;ge, Denmark </aff><aff id="Aff4"><label>4</label>Department of Anaesthesiology, Bispebjerg Hospital, Copenhagen University Hospital, K&#x000f8;benhavn, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>112</elocation-id><history><date date-type="received"><day>29</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>It has been hypothesized that dexamethasone can inhibit persistent postoperative pain, but data on humans is lacking and results from animal studies are conflicting. We explored the effect of 16&#x000a0;mg dexamethasone IV administered preoperatively on persistent pain 1&#x000a0;year after lumbar discectomy.</p></sec><sec><title>Methods</title><p>This is a prospective 1-year follow-up on a single-centre, randomized, and blinded trial exploring the analgesic effect of 16&#x000a0;mg IV dexamethasone or placebo after lumbar discectomy. One year follow-up was a written questionnaire including back and leg pain (VAS 0&#x02013;100&#x000a0;mm), Short Form 36 survey (SF-36), EuroQol 5D (EQ-5D), OSWESTRY Low Back Pain Questionnaire, duration of sick leave, working capability, contentment with surgical result.</p></sec><sec><title>Results</title><p>Response rate was 71% (55 patients) in the dexamethasone group, 58% (44 patients) in the placebo group. Leg pain (VAS) was significantly lower in the placebo group compared to the dexamethasone group: 17 (95% CI 10&#x02013;26) vs 26 (95% CI 19&#x02013;33) mm, respectively (mean difference 9&#x000a0;mm (95% CI &#x02212;1 to 0), (<italic>P</italic>&#x02009;=&#x02009;0.03). No difference regarding back pain. The placebo group reported significantly more improvement of leg pain and were significantly more satisfied with the surgical result. Patients in the dexamethasone group reported significantly higher pain levels in EQ-5D- and Oswestry questionnaires. No difference in the SF-36 survey or daily analgesic consumption.</p></sec><sec><title>Conclusions</title><p>We found significantly higher pain levels in the dexamethasone group compared to placebo 1&#x000a0;year after lumbar disc surgery.</p></sec><sec><title>Trial registration</title><p>Clinicaltrials.gov (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01953978?term=NCT01953978&#x00026;rank=1">NCT01953978</ext-link>). Registered 26 Sep 2013.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dexamethasone</kwd><kwd>Glucocorticoids</kwd><kwd>Persistent postoperative pain</kwd><kwd>Preemptive medicine</kwd><kwd>Spine surgery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005111</institution-id><institution>Rigshospitalet</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>An increasing number of studies have explored the role of glucocorticoids as a potential adjuvant in analgesic regimens for acute postoperative pain management [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Reviews and metaanalyses&#x02019; indicate that dexamethasone in doses of 0.1&#x02013;0.2&#x000a0;mg/kg provides an opioid-sparing effect and lower pain scores after surgery [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Moreover, it is speculated that perioperative administration of glucocorticoids may prevent persistent postoperative pain but follow-up periods have been relatively short and insufficient to detect possible long term beneficial or harmful effects [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>The mechanisms that influence the transition from acute, adaptive postoperative pain to persistent, maladaptive pain are uncertain, but nerve injury and ongoing inflammation play important roles [<xref ref-type="bibr" rid="CR5">5</xref>]. Peripheral- and central sensitizations are fundamental mechanisms of the development of pain chronicity in the postoperative period. Proinflammatory cytokines secreted at or near the site of a nerve injury are involved in the development and maintenance of central sensitization and neuropathic pain [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Glucocorticoids suppress proinflammatory cytokines and induce expression of anti-inflammatory cytokines [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. By inhibiting the release of prostaglandins, and production of proinflammatory cytokines, excitatory amino acids, and growth factors in animal models, glucocorticoids prevent the development of neuropathic pain [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Persistent postsurgical pain is a serious and widely unnoticed clinical problem, difficult to treat and often permanent [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The level of acute postoperative pain is associated with the risk of developing persistent pain [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. However, knowledge of the impact of aggressive, early therapy for persistent, postoperative pain is lacking [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, we aimed to explore the pre-emptive effect of 16&#x000a0;mg dexamethasone IV administered preoperatively on persistent postoperative pain 1&#x000a0;year after lumbar disc surgery.</p></sec><sec id="Sec2"><title>Methods</title><p>This is a prospective 1-year follow up trial on a single-centre, prospective, randomized, and blinded trial exploring the analgesic effect of 16&#x000a0;mg dexamethasone IV on acute postoperative pain after lumbar disc surgery as the main outcome [<xref ref-type="bibr" rid="CR17">17</xref>]. The trial was approved by the Regional Research Ethics Committee and the Danish Data Protection Agency and registered at clinicaltrials.gov (NCT01953978).</p><p>The trial was performed at Glostrup Hospital, Copenhagen University Hospital, Glostrup, Denmark during the period December 7, 2012 to December 7, 2014, and was monitored by the Copenhagen University Hospital Good Clinical Practice Unit. The follow up period was from December 1, 2013 to September 20, 2015. The study fulfilled the guidelines for Good Clinical Practice and the Helsinki Declarations. The protocol, design and reporting of the study complied with the Standard Protocol Items, Recommendations for Interventional Trials (SPIRIT) statement [<xref ref-type="bibr" rid="CR18">18</xref>], and the Consolidated Standards of Reporting Clinical Trials statement (CONSORT) [<xref ref-type="bibr" rid="CR19">19</xref>]. The SF-36 version 1 (freeware) was used for the 1-year follow-up. All patients gave written informed consent before participating in the trial.</p><sec id="Sec3"><title>In- and exclusion criteria</title><p>One hundred-sixty patients undergoing one- or two-level primary lumbar discectomy during general anaesthesia were approached for inclusion in the original trial [<xref ref-type="bibr" rid="CR17">17</xref>]. Inclusion criteria were age 18&#x02013;85 years, American Society of Anaesthesiologists (ASA) physical status classification of I to III, and body mass index between 18 and 40&#x000a0;kg/m2. Exclusion criteria were inability to cooperate, inability to speak or understand Danish, previous spine surgery, pregnancy, allergy to drugs applied in the trial, daily use of systemic steroids or strong opioids (morphine, oxycodone, methadone, fentanyl, or ketobemidone), and alcohol or drug abuse (see also [<xref ref-type="bibr" rid="CR17">17</xref>]).</p></sec><sec id="Sec4"><title>Randomization and blinding</title><p>In the original trial, patients were randomly assigned to one of two groups: Oral paracetamol&#x02009;+&#x02009;oral ibuprofen&#x02009;+&#x02009;IV dexamethasone 16&#x000a0;mg; or oral paracetamol&#x02009;+&#x02009;oral ibuprofen&#x02009;+&#x02009;IV placebo. Randomization was performed by the pharmacy according to a computer-generated block randomization list (each block containing 10 numbers), in a 1:1 ratio. Study medication was pre-packed by the pharmacy in consecutively numbered boxes according to the computer generated randomization list, containing identical 1&#x000a0;ml ampules of either dexamethasone 4&#x000a0;mg/ml (Dexamethasone&#x000ae;, GALEN pharma GmbH, Germany), or isotonic sodium chloride 9&#x000a0;mg/ml. The intervention was blinded to patients, investigators, surgeons, and clinical personnel (for further information, please see [<xref ref-type="bibr" rid="CR17">17</xref>]).</p><p>The randomization code was disclosed until a three months follow-up period had ended, exclusion of patients was decided, and statistical handling of the data was completed, but prior to the 1-year follow-up.</p><p>The primary outcome of the original trial was pain during mobilization 2 to 24&#x000a0;h postoperatively calculated as a &#x02018;weighted average level&#x02019; area under the curve (AUC) (in mm) [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Secondary outcomes included pain at rest (AUC, 2&#x02013;24&#x000a0;h), total morphine consumption 0&#x02013;24&#x000a0;h postoperatively, and 3- and 12-months follow-up (for further information, see [<xref ref-type="bibr" rid="CR17">17</xref>]).</p></sec><sec id="Sec5"><title>One-year follow-up</title><p>The 1-year follow-up was performed by a written questionnaire. The questionnaire was used with permission from Centre for Rheumatology and Spine Diseases, Glostrup University Hospital, Denmark, and the Danish Spine Database. This questionnaire was developed to construct a national database that systematically collects data on patients undergoing spine surgery. The questionnaire consists of demographic data, back and leg pain (VAS 0&#x02013;100&#x000a0;mm), duration of sick leave, working capability and contentment with the results of the operation. Further it contains the following questionnaires: Short form 36 survey (SF-36), EuroQol 5D (EQ-5D) and OSWESTRY Low Back Pain Questionnaire.</p><p>If patients had not returned the questionnaire after three weeks, they received one written reminder.</p></sec><sec id="Sec6"><title>Statistical methods</title><p>We randomized 160 subjects in the original study, and data on acute pain were analysed in 77 and 76 patients in the dexamethasone and placebo groups, respectively [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>For the present data, we used SPSS version 22.0 for Windows (SPSS, Chicago, Illinois) for statistical analysis. Variables were tested for normal distribution with the Kolmogorov-Smirnov test and visual inspection. Data that followed normal distribution were compared using the independent samples t test. The Mann&#x02013;Whitney <italic>U</italic>-test was used for data that were not normally distributed. Categorical data were analyzed using the <italic>x</italic>
<sup>2</sup> test or Fisher&#x02019;s exact test if any cells had expected counts less than five. Data are presented as mean (SD), mean (95% confidence interval), median (lower and upper quartiles) or frequencies (95% confidence interval), as appropriate. A sensitivity analysis was performed for missing data on the VAS pain scores with multiple, average, best case and worst case imputation.</p><p>OSWESTRY Index Score is calculated using the following method: Questions are rated on a scale of 0&#x02013;5 with zero recorded as no disability and five recorded as maximum disability. The scores from all questions are summed, and then multiplied by two to attain an index (range 0&#x02013;100). Zero is then no disability and 100 is maximum disability.</p><p>The SF-36 questionnaire is summarized as two sets of scores: A profile of eight section scores, and two summary scores, one for the physical component (PCS) and one for the mental component (MCS) summary scores. Scores are recalculated to normal zero-to-100 scores for the eight scales and all item scores are oriented so that high scores correspond to better health. All scores are calculated according to the formula described by McDowell [<xref ref-type="bibr" rid="CR20">20</xref>]. Using norm-based scoring (NBS) for the summary scores, each scale is scored to have the same mean (50) and standard deviation (10) as in the general Swedish population, provided by SF-36 organization. Anytime a scale score is below 50, health status is below average relative to the general Swedish population.</p><p>The nature of the hypothesis testing was 2-tailed. P values of less than 0.05 were considered statistically significant. As we consider the results of this 1-year-follow-up trial exploratory, outcomes were not statistically corrected for mass significance. The primary investigator carried out statistical analyses.</p></sec></sec><sec id="Sec7"><title>Results</title><p>All 153 patients included in the original data analysis, 77 and 76 subjects in the dexamethasone and placebo groups, respectively, received a follow-up questionnaire 1&#x000a0;year postoperatively. In the dexamethasone group 55 patients (71%) replied, and in the placebo group 44 patients replied (58%), resulting in an overall response rate of 65% (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Patient characteristics (age, height, weight, preoperative pain, postoperative pain 2&#x02013;24&#x000a0;h and morphine consumption 0&#x02013;24&#x000a0;h) for responders and non-responders were compared with no significant differences between groups.<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT flowchart of trial</p></caption><graphic xlink:href="12871_2016_277_Fig1_HTML" id="MO1"/></fig>
</p><sec id="Sec8"><title>Spine unit questionnaire</title><p>For VAS back pain levels at one year postoperatively, there was no significant difference between groups: 22 (95% CI 16&#x02013;28) vs 20 (95% CI 14&#x02013;28) mm in the dexamethasone and placebo groups, respectively (mean difference 2&#x000a0;mm (95% CI &#x02212;1 to 0), <italic>P</italic>&#x02009;=&#x02009;0.47 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>)). Leg VAS pain levels was significantly lower in the placebo group compared to the dexamethasone group: 17 (95% CI 10&#x02013;26) vs 26 (95% CI 19&#x02013;33) mm, respectively (mean difference 9&#x000a0;mm (95% CI &#x02212;1 to 0), (<italic>P</italic>&#x02009;=&#x02009;0.03) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Postoperative back- and leg pain (VAS). Leg pain 12&#x000a0;months postoperatively was significantly less in the placebo group compared to the dexamethasone group: 17 (95% CI 10&#x02013;26) vs 26 (95% CI 19&#x02013;33) mm, respectively, with a mean difference of 9&#x000a0;mm (95% CI &#x02212;1 to 0), <italic>P</italic>&#x02009;=&#x02009;0.033. There were no other significant differences between groups</p></caption><graphic xlink:href="12871_2016_277_Fig2_HTML" id="MO2"/></fig>
</p><p>Further, when asked how patients evaluated their leg pain today compared to preoperatively, the placebo group reported a significantly higher degree of improvement of their leg pain, compared to the dexamethasone group: 1 (0 &#x02013; 5) vs 2 (0 &#x02013; 5), respectively, (<italic>P</italic>&#x02009;=&#x02009;0.04) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> summarizes multiple, average, best case and worst case imputation for missing data on pain scores.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Follow up 12&#x000a0;months postoperatively</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Dexamethasone</th><th>Placebo</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="4">Patient characteristics</td></tr><tr><td>&#x02003;Number of patients, n</td><td>55</td><td>44</td><td/></tr><tr><td>&#x02003;Response rate, %</td><td>71</td><td>58</td><td/></tr><tr><td>&#x02003;&#x02003;Time from operation to follow up, days</td><td>364 (12)</td><td>366 (11)</td><td>0.31</td></tr><tr><td>&#x02003;&#x02003;Height, cm</td><td>176 (8)</td><td>177 (10)</td><td>0.41</td></tr><tr><td>&#x02003;&#x02003;Weight, kg</td><td>79 (14)</td><td>83 (14)</td><td>0.21</td></tr><tr><td>&#x02003;&#x02003;Sex, f/m</td><td>27/28</td><td>15/29</td><td/></tr><tr><td colspan="4">Outcome</td></tr><tr><td>&#x02003;Back pain now compared to preoperatively</td><td>2 (1 &#x02013; 3)</td><td>2 (1 &#x02013; 2)</td><td>0.19</td></tr><tr><td>&#x02003;Leg pain now compared to preoperatively</td><td>2 (1 &#x02013; 3)</td><td>1 (1 &#x02013; 2)</td><td>0.04</td></tr><tr><td>&#x02003;VAS back pain, 0&#x02013;100&#x000a0;mm</td><td>22 (16&#x02013;28)</td><td>20 (14&#x02013;28)</td><td>0.47</td></tr><tr><td>&#x02003;VAS leg pain, 0&#x02013;100&#x000a0;mm</td><td>26 (19&#x02013;33)</td><td>17 (10&#x02013;26)</td><td>0.03</td></tr><tr><td>&#x02003;Uses analgesics 12&#x000a0;months postoperatively, %</td><td/><td/><td>0.84</td></tr><tr><td>&#x02003;&#x02003;Daily</td><td>16 (7 &#x02013; 27)</td><td>16 (7 &#x02013; 27)</td><td/></tr><tr><td>&#x02003;&#x02003;As needed</td><td>31 (20 &#x02013; 45)</td><td>36 (23 &#x02013; 52)</td><td/></tr><tr><td>&#x02003;Currently on sick leave because of back problem, %</td><td>13 (4 &#x02013; 22)</td><td>5 (0 &#x02013; 11)</td><td>0.17</td></tr><tr><td>&#x02003;Sickleave&#x02009;&#x0003c;&#x02009;3&#x000a0;months postoperatively, %</td><td>79 (58 &#x02013; 81)</td><td>84 (70 &#x02013; 95)</td><td>0.21</td></tr><tr><td>&#x02003;Transferred to less demanding job postoperatively, %</td><td>15 (4 &#x02013; 27)</td><td>19 (8 &#x02013; 32)</td><td>0.59</td></tr><tr><td>&#x02003;Working %</td><td>79 (58 &#x02013; 81)</td><td>84 (61 &#x02013; 87)</td><td>0.89</td></tr><tr><td>&#x02003;Sports active, %</td><td>51 (38 &#x02013; 64)</td><td>68 (48 &#x02013; 77)</td><td>0.09</td></tr><tr><td>&#x02003;Walk distance more than 1000&#x000a0;m, %</td><td>80 (69 &#x02013; 89)</td><td>91 (82 &#x02013; 98)</td><td>0.21</td></tr><tr><td>&#x02003;Satisfaction with surgical result, % (yes/no/unsure)</td><td/><td/><td>0.02</td></tr><tr><td>&#x02003;&#x02003;Satisfied</td><td>66 (51 &#x02013; 79)</td><td>84 (73 &#x02013; 93)</td><td/></tr><tr><td>&#x02003;&#x02003;Unsatisfied</td><td>4 (0 &#x02013; 9)</td><td>7 (0 &#x02013; 14)</td><td/></tr><tr><td>&#x02003;&#x02003;Unsure</td><td>30 (19 &#x02013; 43)</td><td>9 (0 &#x02013; 18)</td><td/></tr></tbody></table><table-wrap-foot><p>Data are mean (SD), mean (95% CI), median (lower and upper quartiles) or frequencies (95% CI). Data were analysed using the students t-test, Mann&#x02013;Whitney <italic>U</italic>-test or the <italic>&#x003c7;</italic>2 test</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Data imputation of pain scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Dexa VAS Back</th><th>Placebo VAS Back</th><th>
<italic>P</italic>-value</th><th>Dexa VAS Leg</th><th>Placebo VAS Leg</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Responders only</td><td>22 (16&#x02013;28)</td><td>20 (14&#x02013;28)</td><td char="." align="char">0.47</td><td>26 (19&#x02013;33)</td><td>17 (10&#x02013;26)</td><td>0.03</td></tr><tr><td>Multiple imputation</td><td>22 (20&#x02013;24)</td><td>20 (18&#x02013;22)</td><td char="." align="char">0.20</td><td>24 (22&#x02013;27)</td><td>17 (16&#x02013;19)</td><td>&#x0003c;0.001</td></tr><tr><td>Average imputation</td><td>22 (18&#x02013;27)</td><td>20 (17&#x02013;24)</td><td char="." align="char">0.53</td><td>25 (20&#x02013;30)</td><td>17 (13&#x02013;21)</td><td>0.03</td></tr><tr><td>Best case imputation</td><td>11 (7&#x02013;16)</td><td>11 (7&#x02013;16)</td><td char="." align="char">1.00</td><td>10 (5&#x02013;15)</td><td>10 (5&#x02013;15)</td><td>1.00</td></tr><tr><td>Worst case imputation</td><td>44 (36&#x02013;53)</td><td>44 (37&#x02013;51)</td><td char="." align="char">1.00</td><td>47 (38&#x02013;56)</td><td>48 (39&#x02013;56)</td><td>0.81</td></tr></tbody></table><table-wrap-foot><p>Data are mean (95% CI)</p></table-wrap-foot></table-wrap>
</p><p>A post hoc analysis of preoperative VAS pain scores and VAS pain during the trial period (weighted average AUC (wAUC) 2&#x02013;24&#x000a0;h), showed that results from the subgroup of patients that completed the 1-year follow-up were similar to the results from the total study population. Only pain during mobilization was significantly different between groups: Dexamethasone compared to placebo, 33 (22) vs 43 (18) mm (wAUC 2&#x02013;24&#x000a0;h) with a mean difference of 10&#x000a0;mm (95% CI 3 to 16), (<italic>P</italic>&#x02009;=&#x02009;0.01) in the original total study population and 32 (20) vs 41 (20) mm with a mean difference of 11&#x000a0;mm (95% CI 2 to 18), (<italic>P</italic>&#x02009;=&#x02009;0.02) in the subgroup of one-year follow-up responders [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>The relation between leg pain levels 3- and 12&#x000a0;months postoperatively are summarized in scatter plots (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The frequency of patients having leg pain (VAS)&#x02009;&#x0003e;&#x02009;30&#x000a0;mm both 3- and 12&#x000a0;months postoperatively was 23% and 8% in the dexamethasone group and placebo group, respectively (<italic>P</italic>&#x02009;=&#x02009;0.07).<fig id="Fig3"><label>Fig. 3</label><caption><p>Scatterplot of leg pain (VAS mm) 3- and 12&#x000a0;months postoperatively</p></caption><graphic xlink:href="12871_2016_277_Fig3_HTML" id="MO3"/></fig>
</p><p>Daily use of analgesics at 1 year postoperatively was not different between groups, with 16% (95% CI 7&#x02013;27) (<italic>P</italic>&#x02009;=&#x02009;0.84) having a daily use of analgesics in both groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Preoperatively, the daily use of analgesics was, 64% (95% CI 51&#x02013;74) in the dexamethasone group and 59% (95% CI 50&#x02013;69) in the placebo group, including only the patients that completed the 1-year follow up.</p><p>Working ability was not significantly different between groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Satisfaction with the surgical result was significantly lower in the dexamethasone group as compared to the placebo group (<italic>P</italic>&#x02009;=&#x02009;0.02) (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec9"><title>Short form 36 survey (SF-36)</title><p>The SF-36 section scores are summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Scores were generally lower in the dexamethasone group indicating poorer health, especially regarding physical health, although there were no significant differences between groups. The physical (PCS) component summary score was mean 46 and 50 in the dexamethasone group and placebo group, respectively, <italic>P</italic>&#x02009;=&#x02009;0.69. The mental (MCS) component summary score was mean 52 and 54 in the dexamethasone group and placebo group, respectively, <italic>P</italic>&#x02009;=&#x02009;0.49.<table-wrap id="Tab3"><label>Table 3</label><caption><p>SF-36, eight section scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Dexamethasone</th><th>Placebo</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="4">Physical health</td></tr><tr><td>&#x02003;Physical function</td><td>75 (50 &#x02013; 75)</td><td>75 (50 &#x02013; 100)</td><td>0.10</td></tr><tr><td>&#x02003;Role physical</td><td>75 (0 &#x02013; 100)</td><td>100 (50 &#x02013; 100)</td><td>0.25</td></tr><tr><td>&#x02003;Bodily pain</td><td>76 (46 &#x02013; 94)</td><td>82 (47 &#x02013; 100)</td><td>0.12</td></tr><tr><td>&#x02003;General health</td><td>68 (43 &#x02013; 80)</td><td>80 (55 &#x02013; 93)</td><td>0.15</td></tr><tr><td colspan="4">Mental health</td></tr><tr><td>&#x02003;Vitality</td><td>60 (40 &#x02013; 80)</td><td>70 (50 &#x02013; 80)</td><td>0.21</td></tr><tr><td>&#x02003;Social function</td><td>100 (72 &#x02013; 100)</td><td>100 (50 &#x02013; 100)</td><td>0.89</td></tr><tr><td>&#x02003;Role emotional</td><td>100 (50 &#x02013; 100)</td><td>100 (50 &#x02013; 100)</td><td>0.41</td></tr><tr><td>&#x02003;Mental health</td><td>70 (58 &#x02013; 90)</td><td>80 (70 &#x02013; 90)</td><td>0.22</td></tr></tbody></table><table-wrap-foot><p>Data are median with lower and upper quartiles. Data were analysed using the Mann&#x02013;Whitney <italic>U</italic>-test. Zero is equivalent to maximum disability and a score of 100 is equivalent to no disability</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>EuroQol 5D (EQ-5D)</title><p>Results from the EQ-5D questionnaire are summarized in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. There was a significant difference in severity of Pain/Discomfort between groups, with 28/67/5% in the dexamethasone group reporting no/moderate/severe pain, respectively, and 50/45/5% in the placebo group reporting no/moderate/severe pain, respectively, (<italic>P</italic>&#x02009;=&#x02009;0.03) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>EuroQol. Significant difference in severity of Pain/Discomfort with 28/67/5% in the dexamethasone group reporting no pain/moderate pain/severe pain respectively and in the placebo group 50/45/5% reported no pain/moderate pain/severe pain respectively, <italic>P</italic>&#x02009;=&#x02009;0.034</p></caption><graphic xlink:href="12871_2016_277_Fig4_HTML" id="MO4"/></fig>
</p><p>There was no significant difference between groups in self-reported health (VAS scale) with medians of 80 (4&#x02013;100) vs 80 (14&#x02013;100) mm in the dexamethasone and placebo groups, respectively, (<italic>P</italic>&#x02009;=&#x02009;0.26).</p></sec><sec id="Sec11"><title>OSWESTRY low back pain questionnaire</title><p>Results from OSWESTRY Low Back Pain Questionnaire are summarized as an Oswestry Index Score 0&#x02013;100, with 0&#x02013;20 being minimal disability and 81&#x02013;100 being patients who are bed-bound. There was no significant difference between groups: Dexamethasone median 14 (0&#x02013;60) vs placebo median 8 (0&#x02013;56), (<italic>P</italic>&#x02009;=&#x02009;0.09), categorizing both groups with minimal disability. However, in the questionnaire, there was a significant difference regarding pain with more severe pain scores in the dexamethasone group: Median 1 (0&#x02013;5) vs placebo median 1 (0&#x02013;3), (<italic>P</italic>&#x02009;=&#x02009;0.01).</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>In this prospective follow-up on a single-centre, prospective, randomized, blinded trial exploring the analgesic effect of 16&#x000a0;mg dexamethasone IV on acute postoperative pain after lumbar disc surgery, we found significantly higher chronic pain levels in the dexamethasone group at one-year postoperatively. Leg pain was significantly higher in the dexamethasone group compared to the placebo group, measured on two different parameters, as in both the EQ-5D and OSWESTRY surveys, questions on pain/discomfort revealed higher scores in the dexamethasone group.</p><p>Further, satisfaction with the surgical result was significantly reduced in the dexamethasone group compared to the placebo group.</p><p>It has been suggested that the potent immunomodulatory benefits of dexamethasone could possibly inhibit the development of chronic pain [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Few clinical trials have investigated this effect of corticosteroids in postoperative patients [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Only one trial, testing a bolus and 4 days of intravenous infusion of hydrocortisone, found a significant positive impact on chronic pain 6&#x000a0;months postoperatively [<xref ref-type="bibr" rid="CR24">24</xref>]. Despite a significant analgesic effect of dexamethasone on acute pain during mobilization 2&#x02013;24&#x000a0;h postoperatively for both the total study population and in the subgroup of 1-year follow-up responders (post hoc analysis), we were not able to demonstrate any inhibitory effects of dexamethasone on chronic pain 1&#x000a0;year postoperatively.</p><p>In contrast we found increased pain levels in the dexamethasone group, specifically leg pain, indicating increased levels of neuropathic pain. In our original trial, 16% (95% CI 7&#x02013;26) versus 8% (95% CI 0&#x02013;17) reported new weakness and/or paralysis of the legs affecting the ability to walk in the dexamethasone and placebo groups, respectively, 3&#x000a0;months postoperatively (<italic>P</italic>&#x02009;=&#x02009;0.20) [<xref ref-type="bibr" rid="CR17">17</xref>]. It is uncertain whether this result is related to our findings of leg pain 1&#x000a0;year postoperatively, but we did find a significantly higher number of patients in the dexamethasone group with leg pain&#x02009;&#x0003e;&#x02009;30&#x000a0;mm both 3- and 12&#x000a0;months postoperatively.</p><p>Recent experimental trials in rats have demonstrated that glucocorticoid receptors in the spinal cord are up-regulated after constriction nerve injury, and imply that glucocorticoids can worsen neuropathic pain behavior [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. These results imply an important function of neuronal glucocorticoid receptors in the mechanisms of neuropathic pain behaviors in rats and suggest a possible role for glucocorticoid receptor antagonists in the treatment of neuropathic pain. Other studies have found that by inhibiting the release of prostaglandins, and production of proinflammatory cytokines, excitatory amino acids, and growth factors in animal models, glucocorticoids prevented the development of neuropathic pain behavior [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, at present, results on the effect of glucocorticoids after nerve injury are conflicting. Even when adjusting for non-responders by data imputation we found no preventive effect of dexamethasone on persistent pain. When performing multiple- and average imputation we found similar results to those of the responders with higher levels of leg pain in the dexamethasone group. When performing best case- and worst case imputations we found no differences between groups.</p><p>Despite significantly higher pain levels in the dexamethasone group we did not find significant differences in ability to work, length of sick leave, disability or self-reported health between groups. However, for both the dexamethasone and placebo groups, pain levels were low in the Spine Unit Questionnaire and EQ-5D, and low to moderate in the Oswestry Index Score for pain.</p><p>Elevated blood glucose levels are a potential concern of glucocorticoids, but the hyperglycemic responses measured in current trials are modest at most. Several large reviews have investigated this risk; and so far, there is no solid evidence that a single dose of glucocorticoids is associated with hyperglycemic responses affecting postoperative morbidity [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Based on this, we did not measure blood glucose in our study.</p><p>A major limitation of this 12&#x000a0;months follow-up study is the response rate of 65%, rendering data with low strength to draw final conclusions on dexamethasone&#x02019;s role in preventing persistent postoperative pain. We do not know the status of patients that did not respond. If patients with high pain levels are more motivated to respond this could potentially lead to a false positive result (type 1 error). However, this should be similar in both groups. We found no differences in patient characteristics between responders and non-responders. Further our imputations of missing data did not contribute with new indications that dexamethasone can prevent persistent postoperative pain. Our study contains exploratory secondary outcomes from an original trial. Thus, the sample size calculation was not performed with regards to these secondary outcomes. Many of the questions in the questionnaires regard the same topic and we would therefore have to do multiple corrections introducing a greater risk of ignoring a relationship that is real and performing a type 2 error. As we consider these outcomes hypothesis generating, we chose not to correct for multiple comparisons and interpret the results with respect to the increased risk of type 1 errors.</p><p>Further this study suffers from the well-known weaknesses of written questionnaires: Suboptimal response rates, a level of subjectivity, recall bias, interpretation of questions, and researcher imposition. The strength of the study is that very few investigators were involved in the trial, leading to few protocol violations, and very few original data missing.</p><p>Future studies on possible effects and safety aspects of dexamethasone on sustained postoperative pain are warranted. We consider our results on back pain incidence after lumbar back surgery as a significant negative finding in this study. The exact dose of glucocorticoids at which potential harm outweighs benefit is still unknown.</p></sec><sec id="Sec13"><title>Conclusions</title><p>In conclusion, we found no inhibitory effect of dexamethasone on chronic pain 1&#x000a0;year after lumbar disc surgery. In contrast we observed significantly higher pain levels in the dexamethasone group compared to placebo, which may be of concern. Our results may be considered as hypothesis generating for future properly sized studies investigating long-term effects of perioperative glucocorticoids on human postoperative pain.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ASA</term><def><p>American Society of Anaesthesiologists</p></def></def-item><def-item><term>AUC</term><def><p>Area under the curve</p></def></def-item><def-item><term>CI</term><def><p>Conficence interval</p></def></def-item><def-item><term>EQ-5D</term><def><p>EuroQol 5D</p></def></def-item><def-item><term>MCS</term><def><p>mental component summary score</p></def></def-item><def-item><term>NBS</term><def><p>Norm-based scoring</p></def></def-item><def-item><term>PCS</term><def><p>Physical component summary score</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SF-36</term><def><p>Short Form 36 survey</p></def></def-item><def-item><term>VAS</term><def><p>Visual analogue scale</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We gratefully thank Centre for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Copenhagen University Hospital and the DaneSpine registry for their assistance. We also thank the Department of Neuroanaesthesiology, Rigshospitalet - Glostrup, Copenhagen University Hospital, Denmark for their support.</p><sec id="FPar1"><title>Funding</title><p>This trial was funded by the Department of Neuroanaesthesiology, Rigshospitalet - Glostrup, Copenhagen University Hospital.</p></sec><sec id="FPar2"><title>Availability of data and material</title><p>The dataset supporting the conclusions of this article is available by request to the corresponding author Dr. Rikke Vibeke Nielsen by e-mail: rikkevibeke@gmail.com.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>RVN: Study design, primary investigator, patient recruitment, data collection, care for study patients, data analysis and writing the paper. JSF: Study design, patient recruitment, care for study patients, data collection, writing the paper. OM: Study design, scientific advisors, data analysis, writing the paper. JBD: Study design, scientific advisors, data analysis, writing the paper. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The trial was approved by the Regional Research Ethics Committee (identification number: H-2-2012-125). Only patients who had given their informed consent to participate were included.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>GS</given-names><suffix>Jr</suffix></name><name><surname>Almeida</surname><given-names>MD</given-names></name><name><surname>Benzon</surname><given-names>HT</given-names></name><name><surname>McCarthy</surname><given-names>RJ</given-names></name></person-group><article-title>Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials</article-title><source>Anesthesiology</source><year>2011</year><volume>115</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e31822a24c2</pub-id><pub-id pub-id-type="pmid">21799397</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldron</surname><given-names>NH</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Gan</surname><given-names>TJ</given-names></name><name><surname>Allen</surname><given-names>TK</given-names></name><name><surname>Habib</surname><given-names>AS</given-names></name></person-group><article-title>Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis</article-title><source>Br J Anaesth</source><year>2013</year><volume>110</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1093/bja/aes431</pub-id><pub-id pub-id-type="pmid">23220857</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romundstad</surname><given-names>L</given-names></name><name><surname>Stubhaug</surname><given-names>A</given-names></name></person-group><article-title>Glucocorticoids for acute and persistent postoperative neuropathic pain: what is the evidence?</article-title><source>Anesthesiology</source><year>2007</year><volume>107</volume><fpage>371</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1097/01.anes.0000279487.27940.5c</pub-id><pub-id pub-id-type="pmid">17721239</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>GS</given-names><suffix>Jr</suffix></name><name><surname>Bialek</surname><given-names>JM</given-names></name><name><surname>Turan</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>RJ</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name></person-group><article-title>Perioperative Dexamethasone and the Development of Chronic Postmastectomy Pain: A Single-Center Observational Cohort Study</article-title><source>Reg Anesth Pain Med</source><year>2015</year><volume>40</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1097/AAP.0000000000000301</pub-id><pub-id pub-id-type="pmid">26263077</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehlet</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><article-title>Persistent postsurgical pain: risk factors and prevention</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>1618</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68700-X</pub-id><pub-id pub-id-type="pmid">16698416</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JM</given-names></name><name><surname>An</surname><given-names>J</given-names></name></person-group><article-title>Cytokines, inflammation, and pain</article-title><source>Int Anesthesiol Clin</source><year>2007</year><volume>45</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1097/AIA.0b013e318034194e</pub-id><pub-id pub-id-type="pmid">17426506</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>SH</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Lorenzetti</surname><given-names>BB</given-names></name><name><surname>Michelin</surname><given-names>MA</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>Flower</surname><given-names>RJ</given-names></name><name><surname>Poole</surname><given-names>S</given-names></name></person-group><article-title>Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone</article-title><source>Br J Pharmacol</source><year>1997</year><volume>121</volume><fpage>883</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0701211</pub-id><pub-id pub-id-type="pmid">9222544</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Strong</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>JM</given-names></name></person-group><article-title>Systemic antiinflammatory corticosteroid reduces mechanical pain behavior, sympathetic sprouting, and elevation of proinflammatory cytokines in a rat model of neuropathic pain</article-title><source>Anesthesiology</source><year>2007</year><volume>107</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1097/01.anes.0000278907.37774.8d</pub-id><pub-id pub-id-type="pmid">17721250</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Xuan</surname><given-names>H</given-names></name><name><surname>Chou</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>R</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Betamethasone affects cerebral expressions of NF-kappaB and cytokines that correlate with pain behavior in a rat model of neuropathy</article-title><source>Ann Clin Lab Sci</source><year>2006</year><volume>36</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">16501235</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Sawamura</surname><given-names>S</given-names></name><name><surname>Sekiyama</surname><given-names>H</given-names></name><name><surname>Tamai</surname><given-names>H</given-names></name><name><surname>Hanaoka</surname><given-names>K</given-names></name></person-group><article-title>Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats</article-title><source>Anesthesiology</source><year>2004</year><volume>100</volume><fpage>1249</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1097/00000542-200405000-00029</pub-id><pub-id pub-id-type="pmid">15114224</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddi</surname><given-names>D</given-names></name><name><surname>Curran</surname><given-names>N</given-names></name></person-group><article-title>Chronic pain after surgery: pathophysiology, risk factors and prevention</article-title><source>Postgrad Med J</source><year>2014</year><volume>90</volume><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1136/postgradmedj-2013-132215</pub-id><pub-id pub-id-type="pmid">24572639</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Ven</surname><given-names>TJ</given-names></name><name><surname>John Hsia</surname><given-names>HL</given-names></name></person-group><article-title>Causes and prevention of chronic postsurgical pain</article-title><source>Curr Opin Crit Care</source><year>2012</year><volume>18</volume><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e3283557a7f</pub-id><pub-id pub-id-type="pmid">22732437</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolajsen</surname><given-names>L</given-names></name><name><surname>Sorensen</surname><given-names>HC</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Kehlet</surname><given-names>H</given-names></name></person-group><article-title>Chronic pain following Caesarean section</article-title><source>Acta Anaesthesiol Scand</source><year>2004</year><volume>48</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2004.00271.x</pub-id><pub-id pub-id-type="pmid">14674981</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Thornton</surname><given-names>AJ</given-names></name><name><surname>Powell</surname><given-names>R</given-names></name><name><surname>Johnston</surname><given-names>M</given-names></name><name><surname>Wells</surname><given-names>M</given-names></name><name><surname>Heys</surname><given-names>SD</given-names></name><name><surname>Thompson</surname><given-names>AM</given-names></name><name><surname>Cairns Smith</surname><given-names>W</given-names></name><name><surname>Chambers</surname><given-names>WA</given-names></name><name><surname>Scott</surname><given-names>NW</given-names></name><name><surname>Recovery Study</surname><given-names>G</given-names></name></person-group><article-title>Psychological, surgical, and sociodemographic predictors of pain outcomes after breast cancer surgery: a population-based cohort study</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.09.028</pub-id><pub-id pub-id-type="pmid">24099954</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoda</surname><given-names>Y</given-names></name><name><surname>Kambara</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Kishi</surname><given-names>Y</given-names></name><name><surname>Kodama</surname><given-names>K</given-names></name><name><surname>Koyama</surname><given-names>T</given-names></name></person-group><article-title>The morbidity, time course and predictive factors for persistent post-thoracotomy pain</article-title><source>Eur J Pain</source><year>2001</year><volume>5</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1053/eujp.2001.0225</pub-id><pub-id pub-id-type="pmid">11394926</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>I</given-names></name><name><surname>Hah</surname><given-names>J</given-names></name><name><surname>Mackey</surname><given-names>S</given-names></name><name><surname>Ottestad</surname><given-names>E</given-names></name><name><surname>Kong</surname><given-names>JT</given-names></name><name><surname>Lahidji</surname><given-names>S</given-names></name><name><surname>Tawfik</surname><given-names>V</given-names></name><name><surname>Younger</surname><given-names>J</given-names></name><name><surname>Curtin</surname><given-names>C</given-names></name></person-group><article-title>Perioperative interventions to reduce chronic postsurgical pain</article-title><source>J Reconstr Microsurg</source><year>2013</year><volume>29</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1329921</pub-id><pub-id pub-id-type="pmid">23463498</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>RV</given-names></name><name><surname>Siegel</surname><given-names>H</given-names></name><name><surname>Fomsgaard</surname><given-names>JS</given-names></name><name><surname>Andersen</surname><given-names>JD</given-names></name><name><surname>Martusevicius</surname><given-names>R</given-names></name><name><surname>Mathiesen</surname><given-names>O</given-names></name><name><surname>Dahl</surname><given-names>JB</given-names></name></person-group><article-title>Preoperative dexamethasone reduces acute but not sustained pain after lumbar disk surgery: a randomized, blinded, placebo-controlled trial</article-title><source>Pain</source><year>2015</year><volume>156</volume><fpage>2538</fpage><lpage>2544</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000326</pub-id><pub-id pub-id-type="pmid">26270586</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Laupacis</surname><given-names>A</given-names></name><name><surname>Gotzsche</surname><given-names>PC</given-names></name><name><surname>Krleza-Jeric</surname><given-names>K</given-names></name><name><surname>Hrobjartsson</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>H</given-names></name><name><surname>Dickersin</surname><given-names>K</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><etal/></person-group><article-title>SPIRIT 2013 statement: defining standard protocol items for clinical trials</article-title><source>Ann Intern Med</source><year>2013</year><volume>158</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id><pub-id pub-id-type="pmid">23295957</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1191</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04337-3</pub-id><pub-id pub-id-type="pmid">11323066</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>I M</collab></person-group><source>Measuring Health: A guide to rating scales and questionnaires</source><year>2006</year><edition>1</edition><publisher-loc>USA</publisher-loc><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaparro</surname><given-names>LE</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Wiffen</surname><given-names>PJ</given-names></name><name><surname>Gilron</surname><given-names>I</given-names></name></person-group><article-title>Pharmacotherapy for the prevention of chronic pain after surgery in adults</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>7</volume><fpage>CD008307</fpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>SG</given-names></name><name><surname>Kardash</surname><given-names>KJ</given-names></name><name><surname>Huk</surname><given-names>OL</given-names></name><name><surname>Zukor</surname><given-names>DJ</given-names></name><name><surname>Antoniou</surname><given-names>J</given-names></name></person-group><article-title>Perioperative dexamethasone does not affect functional outcome in total hip arthroplasty</article-title><source>Clin Orthop Relat Res</source><year>2009</year><volume>467</volume><fpage>1463</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1007/s11999-009-0733-x</pub-id><pub-id pub-id-type="pmid">19224304</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romundstad</surname><given-names>L</given-names></name><name><surname>Breivik</surname><given-names>H</given-names></name><name><surname>Roald</surname><given-names>H</given-names></name><name><surname>Skolleborg</surname><given-names>K</given-names></name><name><surname>Romundstad</surname><given-names>PR</given-names></name><name><surname>Stubhaug</surname><given-names>A</given-names></name></person-group><article-title>Chronic pain and sensory changes after augmentation mammoplasty: long term effects of preincisional administration of methylprednisolone</article-title><source>Pain</source><year>2006</year><volume>124</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2006.03.020</pub-id><pub-id pub-id-type="pmid">16650580</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>F</given-names></name><name><surname>Kilger</surname><given-names>E</given-names></name><name><surname>Roozendaal</surname><given-names>B</given-names></name><name><surname>de Quervain</surname><given-names>DJ</given-names></name><name><surname>Lamm</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Schmolz</surname><given-names>M</given-names></name><name><surname>Briegel</surname><given-names>J</given-names></name><name><surname>Schelling</surname><given-names>G</given-names></name></person-group><article-title>Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study</article-title><source>J Thorac Cardiovasc Surg</source><year>2006</year><volume>131</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2005.07.063</pub-id><pub-id pub-id-type="pmid">16434254</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turan</surname><given-names>A</given-names></name><name><surname>Belley-Cote</surname><given-names>EP</given-names></name><name><surname>Vincent</surname><given-names>J</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>van Oostveen</surname><given-names>R</given-names></name><name><surname>Cordova</surname><given-names>G</given-names></name><name><surname>Yared</surname><given-names>JP</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery</article-title><source>Anesthesiology</source><year>2015</year><volume>123</volume><fpage>1404</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000000915</pub-id><pub-id pub-id-type="pmid">26501386</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name><name><surname>Ai</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><article-title>Expression of central glucocorticoid receptors after peripheral nerve injury contributes to neuropathic pain behaviors in rats</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>8595</fpage><lpage>8605</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3058-04.2004</pub-id><pub-id pub-id-type="pmid">15456833</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><article-title>Central glucocorticoid receptors modulate the expression and function of spinal NMDA receptors after peripheral nerve injury</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4127-04.2005</pub-id><pub-id pub-id-type="pmid">15647493</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><article-title>Spinal glucocorticoid receptors contribute to the development of morphine tolerance in rats</article-title><source>Anesthesiology</source><year>2005</year><volume>102</volume><fpage>832</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1097/00000542-200504000-00020</pub-id><pub-id pub-id-type="pmid">15791114</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>G</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><article-title>Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats</article-title><source>Pain</source><year>2007</year><volume>131</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2006.12.019</pub-id><pub-id pub-id-type="pmid">17258396</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiesen</surname><given-names>O</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Kontinen</surname><given-names>VK</given-names></name><name><surname>Pommergaard</surname><given-names>HC</given-names></name><name><surname>Nikolajsen</surname><given-names>L</given-names></name><name><surname>Rosenberg</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>MS</given-names></name><name><surname>Hamunen</surname><given-names>K</given-names></name><name><surname>Kjer</surname><given-names>JJ</given-names></name><name><surname>Dahl</surname><given-names>JB</given-names></name><collab>Scandinavian Postoperative Pain A</collab></person-group><article-title>Adverse effects of perioperative paracetamol, NSAIDs, glucocorticoids, gabapentinoids and their combinations: a topical review</article-title><source>Acta Anaesthesiol Scand</source><year>2014</year><volume>58</volume><fpage>1182</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1111/aas.12380</pub-id><pub-id pub-id-type="pmid">25116762</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitlock</surname><given-names>RP</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Teoh</surname><given-names>KH</given-names></name><name><surname>Lamy</surname><given-names>A</given-names></name><name><surname>Vincent</surname><given-names>J</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><name><surname>Paparella</surname><given-names>D</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name><name><surname>Karthikeyan</surname><given-names>G</given-names></name><name><surname>Villar</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>1243</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00273-1</pub-id><pub-id pub-id-type="pmid">26460660</pub-id></element-citation></ref></ref-list></back></article>